{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:40:09Z","timestamp":1792460409219,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"DOI":"10.1007\/s42000-026-00780-5","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:52:57Z","timestamp":1792414377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antidiabetic medications in the pipeline"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7345-7912","authenticated-orcid":false,"given":"Zoe A.","family":"Efstathiadou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-5959","authenticated-orcid":false,"given":"Apostolos I.","family":"Gogakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Divaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Makri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"1","key":"780_CR1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13098-025-01796-4","volume":"17","author":"AF Godoy-Matos","year":"2025","unstructured":"Godoy-Matos AF, Val\u00e9rio CM, J\u00fanior WSS, de Araujo-Neto JM, Sposito AC, Suassuna JHR (2025) CARDIAL-MS (cardio-renal-diabetes-liver-metabolic syndrome): a new proposition for an integrated multisystem metabolic disease. Diabetol Metab Syndr 17(1):218. https:\/\/doi.org\/10.1186\/s13098-025-01796-4","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"780_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00125-025-06581-6","volume":"69","author":"CJ Bailey","year":"2026","unstructured":"Bailey CJ (2026) Pharmacological therapies for type 2 diabetes: future approaches. Diabetologia 69(1):20\u201335. https:\/\/doi.org\/10.1007\/s00125-025-06581-6","journal-title":"Diabetologia"},{"key":"780_CR3","doi-asserted-by":"publisher","first-page":"E4333","DOI":"10.1210\/clinem\/dgac499","volume":"107","author":"G Mingrone","year":"2022","unstructured":"Mingrone G, Castagneto-Gissey L, Bornstein SR (2022) New horizons: emerging antidiabetic medications. J Clin Endocrinol Metab 107:E4333\u2013E4340. https:\/\/doi.org\/10.1210\/clinem\/dgac499","journal-title":"J Clin Endocrinol Metab"},{"key":"780_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","volume":"13","author":"S Wharton","year":"2025","unstructured":"Wharton S, Freitas P, Hjelmes\u00e6th J, Kabisch M, Kandler K, Lingvay I, Quiroga M, Rosenstock J, Garvey WT (2025) Once-weekly semaglutide 7\u00b72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 13:949\u2013963. https:\/\/doi.org\/10.1016\/S2213-8587(25)00226-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"780_CR5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S2213-8587(25)00225-6","volume":"13","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, Bergenheim SJ, Buse JB, Freitas P, Garvey WT, Harder-Lauridsen NM, Rosenstock J, Sahu K, Wharton S (2025) Once-weekly semaglutide 7\u00b72 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 13:935\u2013948. https:\/\/doi.org\/10.1016\/S2213-8587(25)00225-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"780_CR6","doi-asserted-by":"publisher","unstructured":"Aroda VR, J\u00f8rgensen NB, Kumar B, Lingvay I, Laulund AS, Buse JB (2025) High-dose semaglutide (Up to 16 mg) in people with type 2 diabetes and overweight or obesity: a randomized, placebo-controlled, phase 2 trial. Diabetes Care 48. https:\/\/doi.org\/10.2337\/dc24-2425","DOI":"10.2337\/dc24-2425"},{"key":"780_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/nejmoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M (2023) Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 389:877\u2013888. https:\/\/doi.org\/10.1056\/nejmoa2302392","journal-title":"N Engl J Med"},{"key":"780_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, Robins D (2023) Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet 402:472\u2013483. https:\/\/doi.org\/10.1016\/S0140-6736(23)01302-8","journal-title":"Lancet"},{"key":"780_CR9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/nejmoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu W-S, Liu R, Li J, Fern\u00e1ndez Land\u00f3 L, Denning M, Ludwig L, Chen Y (2025) Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med 393:1065\u20131076. https:\/\/doi.org\/10.1056\/nejmoa2505669","journal-title":"N Engl J Med"},{"key":"780_CR10","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/s0140-6736(25)02165-8","volume":"406","author":"DB Horn","year":"2025","unstructured":"Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, Aberle J, Bain SC, Allen S, Sarker E, Wu Q, Stefanski A, Jouravskaya I (2025) Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet 406:2927\u20132944. https:\/\/doi.org\/10.1016\/s0140-6736(25)02165-8","journal-title":"Lancet"},{"key":"780_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S2213-8587(25)00141-X","volume":"13","author":"L Ji","year":"2025","unstructured":"Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, Huang C, Lian Q, Yuan M, Gao G, Lu Y, Han J, Fu W, Wang H, Zhang Y, Shi X, Wen B, Shi B, Hu W, Guo T, Xing Y, Li Y, Li Q, Zheng Q, Yang M, Ning J, Guo M, Li Y, Pan H (2025) Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 13:777\u2013789. https:\/\/doi.org\/10.1016\/S2213-8587(25)00141-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"780_CR12","doi-asserted-by":"publisher","first-page":"171380","DOI":"10.1016\/J.PEPTIDES.2025.171380","volume":"187","author":"CJ Bailey","year":"2025","unstructured":"Bailey CJ, Flatt PR, Conlon JM (2025) Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides (NY) 187:171380. https:\/\/doi.org\/10.1016\/J.PEPTIDES.2025.171380","journal-title":"Peptides (NY)"},{"key":"780_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","volume":"12","author":"CW le Roux","year":"2024","unstructured":"le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM (2024) Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 12:162\u2013173. https:\/\/doi.org\/10.1016\/S2213-8587(23)00356-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"780_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","volume":"67","author":"M Bl\u00fcher","year":"2024","unstructured":"Bl\u00fcher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM (2024) Dose\u2013response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia 67:470\u2013482. https:\/\/doi.org\/10.1007\/s00125-023-06053-9","journal-title":"Diabetologia"},{"key":"780_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R (2024) A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 391:311\u2013319. https:\/\/doi.org\/10.1056\/nejmoa2401755","journal-title":"N Engl J Med"},{"key":"780_CR16","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/nejmoa2411528","volume":"392","author":"L Ji","year":"2025","unstructured":"Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, Zhao Y, Qiu W, Huang C, Chen L, Zhong S, Han J, Zhang Y, Lian Q, Yang P, Lv L, Gu J, Liu Z, Deng H, Wang Y, Li L, Pei L, Qian L (2025) Once-weekly mazdutide in chinese adults with obesity or overweight. N Engl J Med 392:2215\u20132225. https:\/\/doi.org\/10.1056\/nejmoa2411528","journal-title":"N Engl J Med"},{"key":"780_CR17","doi-asserted-by":"publisher","first-page":"108150","DOI":"10.1016\/j.cct.2025.108150","volume":"160","author":"Y Luo","year":"2026","unstructured":"Luo Y, Jiang H, Shi B, Cai H, Wang H, Li S, Qiu W, Li Y, Zhou R, Deng H, Guo Q, Li L, Pei L, Zhang HH, Qian L, Ji L (2026) Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemp Clin Trials 160:108150. https:\/\/doi.org\/10.1016\/j.cct.2025.108150","journal-title":"Contemp Clin Trials"},{"key":"780_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/nejmoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML (2023) Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 A Phase 2 Trial. N Engl J Med 389:514\u2013526. https:\/\/doi.org\/10.1056\/nejmoa2301972","journal-title":"N Engl J Med"},{"key":"780_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet 402:529\u2013544. https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X","journal-title":"The Lancet"},{"key":"780_CR20","doi-asserted-by":"publisher","first-page":"bnz002","DOI":"10.1210\/endrev\/bnz002","volume":"41","author":"EA Killion","year":"2020","unstructured":"Killion EA, Lu SC, Fort M, Yamada Y, V\u00e9niant MM, Lloyd DJ (2020) Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists = antagonists? Endocr Rev 41:bnz002. https:\/\/doi.org\/10.1210\/endrev\/bnz002","journal-title":"Endocr Rev"},{"key":"780_CR21","doi-asserted-by":"publisher","first-page":"e230339","DOI":"10.1530\/JOE-23-0339","volume":"262","author":"RA Lafferty","year":"2024","unstructured":"Lafferty RA, Flatt PR, Gault VA, Irwin N (2024) Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes? J Endocrinol 262:e230339. https:\/\/doi.org\/10.1530\/JOE-23-0339","journal-title":"J Endocrinol"},{"key":"780_CR22","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1128\/mcb.00256-14","volume":"34","author":"S Mohammad","year":"2014","unstructured":"Mohammad S, Patel RT, Bruno J, Panhwar MS, Wen J, McGraw TE (2014) A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity. Mol Cell Biol 34:3618\u20133629. https:\/\/doi.org\/10.1128\/mcb.00256-14","journal-title":"Mol Cell Biol"},{"key":"780_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/nejmoa2504214","volume":"393","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, Ross L, Liu Y, Burns CE, Abbasi SA, Pannacciulli N (2025) Once-monthly maridebart cafraglutide for the treatment of obesity \u2014 A Phase 2 Trial. N Engl J Med 393:843\u2013857. https:\/\/doi.org\/10.1056\/nejmoa2504214","journal-title":"N Engl J Med"},{"key":"780_CR24","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.2337\/dc08-0029","volume":"31","author":"SR Smith","year":"2008","unstructured":"Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C (2008) Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 31:1816\u20131823. https:\/\/doi.org\/10.2337\/dc08-0029","journal-title":"Diabetes Care"},{"issue":"51","key":"780_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/15209150252924094","volume":"4","author":"RE Ratner","year":"2002","unstructured":"Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG (2002) Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 4(51):61. https:\/\/doi.org\/10.1089\/15209150252924094","journal-title":"Diabetes Technol Ther"},{"key":"780_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M (2023) Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet 402:720\u2013730. https:\/\/doi.org\/10.1016\/S0140-6736(23)01163-7","journal-title":"The Lancet"},{"key":"780_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/nejmoa2502081","volume":"393","author":"WT Garvey","year":"2025","unstructured":"Garvey WT, Bl\u00fcher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietil\u00e4inen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH (2025) Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New Engl J Med 393:635\u2013647. https:\/\/doi.org\/10.1056\/nejmoa2502081","journal-title":"New Engl J Med"},{"key":"780_CR28","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1056\/nejmoa2502082","volume":"393","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, Lingvay I, Lyndgaard CB, Rosenstock J, Pedersen SD (2025) Cagrilintide-semaglutide in adults with overweight or obesity and Type 2 diabetes. N Engl J Med 393:648\u2013659. https:\/\/doi.org\/10.1056\/nejmoa2502082","journal-title":"N Engl J Med"},{"key":"780_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00125-024-06348-5","volume":"68","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, Benamar M, Chen L, Fu A, J\u00f3dar E, Nishida T, Riveline JP, Yabe D, Zueger T, R\u00e9a R (2025) Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. Diabetologia 68:739\u2013751. https:\/\/doi.org\/10.1007\/s00125-024-06348-5","journal-title":"Diabetologia"},{"key":"780_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/J.AED.2025.07.012","volume":"12","author":"ABM Kamrul-Hasan","year":"2025","unstructured":"Kamrul-Hasan ABM, Chatterjee S, Nagendra L, Patra S, Dutta D, Aljaberi A, Pappachan JM (2025) Efficacy and safety of once-weekly IcoSema in adults with Type 2 diabetes: a systematic review and meta-analysis. AACE Endocrinol Diabetes 12:153\u2013161. https:\/\/doi.org\/10.1016\/J.AED.2025.07.012","journal-title":"AACE Endocrinol Diabetes"},{"key":"780_CR31","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40261-024-01405-8","volume":"44","author":"L Westergaard","year":"2024","unstructured":"Westergaard L, Alifrangis L, Buckley ST, Coester HV, Klitgaard T, Kristensen NR, Nishimura E, N\u00f8rgreen L, Rocha TMP, Steensgaard DB, Vegge A, Plum-M\u00f6rschel L (2024) Pharmacokinetic properties of a once-weekly fixed-ratio combination of Insulin Icodec and Semaglutide compared with separate administration of each component in individuals with Type 2 diabetes mellitus. Clin Drug Investig 44:849\u2013861. https:\/\/doi.org\/10.1007\/s40261-024-01405-8","journal-title":"Clin Drug Investig"},{"key":"780_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/nejmoa2303208","volume":"389","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Bain SC, Gowda A, J\u00f3dar E, Liang B, Lingvay I, Nishida T, Trevisan R, Mosenzon O (2023) Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med 389:297\u2013308. https:\/\/doi.org\/10.1056\/nejmoa2303208","journal-title":"N Engl J Med"},{"key":"780_CR33","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0140-6736(23)02179-7","volume":"402","author":"D Russell-Jones","year":"2023","unstructured":"Russell-Jones D, Babazono T, Cailleteau R, Engberg S, Irace C, Kjaersgaard MIS, Mathieu C, Rosenstock J, Woo V, Klonoff DC (2023) Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet 402:1636\u20131647. https:\/\/doi.org\/10.1016\/S0140-6736(23)02179-7","journal-title":"Lancet"},{"key":"780_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jama.2023.11313","volume":"330","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Asong M, Desouza C, Gourdy P, Kar S, Vianna A, Vilsb\u00f8ll T, Vinther S, Mu Y (2023) Once-Weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA 330:228\u2013237. https:\/\/doi.org\/10.1001\/jama.2023.11313","journal-title":"JAMA"},{"key":"780_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/nejmoa2502796","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Bailey T, Connery L, Miller E, Desouza C, Wang Q, Leohr J, Knights A, Carr MC, Child CJ (2025) Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy. N Engl J Med 393:325\u2013335. https:\/\/doi.org\/10.1056\/nejmoa2502796","journal-title":"N Engl J Med"},{"key":"780_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41591-022-01802-6","volume":"28","author":"D Zhu","year":"2022","unstructured":"Zhu D, Li X, Ma J, Zeng J, Gan S, Dong X, Yang J, Lin X, Cai H, Song W, Li X, Zhang K, Zhang Q, Lu Y, Bu R, Shao H, Wang G, Yuan G, Ran X, Liao L, Zhao W, Li P, Sun L, Shi L, Jiang Z, Xue Y, Jiang H, Li Q, Li Z, Fu M, Liang Z, Guo L, Liu M, Xu C, Li W, Yu X, Qin G, Yang Z, Su B, Zeng L, Geng H, Shi Y, Zhao Y, Zhang Y, Yang W, Chen L (2022) Dorzagliatin in drug-na\u00efve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 28:965\u2013973. https:\/\/doi.org\/10.1038\/s41591-022-01802-6","journal-title":"Nat Med"},{"key":"780_CR37","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41591-022-01803-5","volume":"28","author":"W Yang","year":"2022","unstructured":"Yang W, Zhu D, Gan S, Dong X, Su J, Li W, Jiang H, Zhao W, Yao M, Song W, Lu Y, Zhang X, Li H, Wang G, Qiu W, Yuan G, Ma J, Li W, Li Z, Wang X, Zeng J, Yang Z, Liu J, Liang Y, Lu S, Zhang H, Liu H, Liu P, Fan K, Jiang X, Li Y, Su Q, Ning T, Tan H, An Z, Jiang Z, Liu L, Zhou Z, Zhang Q, Li X, Shan Z, Xue Y, Mao H, Shi L, Ye S, Zhang X, Sun J, Li P, Yang T, Li F, Lin J, Zhang Z, Zhao Y, Li R, Guo X, Yao Q, Lu W, Qu S, Li H, Tan L, Wang W, Yao Y, Chen D, Li Y, Gao J, Hu W, Fei X, Wu T, Dong S, Jin W, Li C, Zhao D, Feng B, Zhao Y, Zhang Y, Li X, Chen L (2022) Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 28:974\u2013981. https:\/\/doi.org\/10.1038\/s41591-022-01803-5","journal-title":"Nat Med"},{"key":"780_CR38","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1080\/14656566.2021.1974401","volume":"22","author":"S Kaneko","year":"2021","unstructured":"Kaneko S (2021) Novel approaches to pharmacological management of type 2 diabetes in Japan. Expert Opin Pharmacother 22:2235\u20132249. https:\/\/doi.org\/10.1080\/14656566.2021.1974401","journal-title":"Expert Opin Pharmacother"},{"key":"780_CR39","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/dom.14613","volume":"24","author":"J Dubourg","year":"2022","unstructured":"Dubourg J, Fouqueray P, Quinslot D, Grouin JM, Kaku K (2022) Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week, open-label, multicentre phase 3 trial. Diabetes Obes Metab 24:609\u2013619. https:\/\/doi.org\/10.1111\/dom.14613","journal-title":"Diabetes Obes Metab"},{"key":"780_CR40","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/dom.14642","volume":"24","author":"C Reilhac","year":"2022","unstructured":"Reilhac C, Dubourg J, Thang C, Grouin JM, Fouqueray P, Watada H (2022) Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): a randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes Obes Metab 24:838\u2013848. https:\/\/doi.org\/10.1111\/dom.14642","journal-title":"Diabetes Obes Metab"},{"key":"780_CR41","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.scib.2021.02.027","volume":"66","author":"W Jia","year":"2021","unstructured":"Jia W, Ma J, Miao H, Wang C, Wang X, Li Q, Lu W, Yang J, Zhang L, Yang J, Wang G, Zhang X, Zhang M, Sun L, Yu X, Du J, Shi B, Xiao C, Zhu D, Liu H, Zhong L, Xu C, Xu Q, Liang G, Zhang Y, Li G, Gu M, Liu J, Yuan G, Yan Z, Yan D, Ye S, Zhang F, Ning Z, Cao H, Pan D, Yao H, Lu X, Ji L (2021) Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). Sci Bull (Beijing) 66:1581\u20131590. https:\/\/doi.org\/10.1016\/j.scib.2021.02.027","journal-title":"Sci Bull (Beijing)"},{"key":"780_CR42","doi-asserted-by":"publisher","first-page":"e13484","DOI":"10.1111\/1753-0407.13484","volume":"16","author":"Z Ning","year":"2024","unstructured":"Ning Z, Ai G, Chen B, Yao H, Cao H, Pan D, Lu X (2024) Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: a pooled data analysis from two phase III trials. J Diabetes 16:e13484. https:\/\/doi.org\/10.1111\/1753-0407.13484","journal-title":"J Diabetes"},{"key":"780_CR43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40265-025-02150-8","volume":"85","author":"TP Foster","year":"2025","unstructured":"Foster TP, Bruggeman BS, Haller MJ (2025) Emerging immunotherapies for disease modification of type 1 diabetes. Drugs 85:457\u2013473. https:\/\/doi.org\/10.1007\/s40265-025-02150-8","journal-title":"Drugs"},{"key":"780_CR44","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler A-G, Greenbaum CJ (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381:603\u2013613. https:\/\/doi.org\/10.1056\/NEJMoa1902226","journal-title":"N Engl J Med"},{"key":"780_CR45","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","volume":"389","author":"M Waibel","year":"2023","unstructured":"Waibel M, Wentworth JM, So M, Couper JJ, Cameron FJ, MacIsaac RJ, Atlas G, Gorelik A, Litwak S, Sanz-Villanueva L, Trivedi P, Ahmed S, Martin FJ, Doyle ME, Harbison JE, Hall C, Krishnamurthy B, Colman PG, Harrison LC, Thomas HE, Kay TWH (2023) Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes. N Engl J Med 389:2140\u20132150. https:\/\/doi.org\/10.1056\/NEJMoa2306691","journal-title":"N Engl J Med"},{"key":"780_CR46","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1056\/nejmoa2506549","volume":"393","author":"TW Reichman","year":"2025","unstructured":"Reichman TW, Markmann JF, Odorico J, Witkowski P, Fung JJ, Wijkstrom M, Kandeel F, de Koning EJP, Peters AL, Mathieu C, Kean LS, Bruinsma BG, Wang C, Mascia M, Sanna B, Marigowda G, Pagliuca F, Melton D, Ricordi C, Rickels MR (2025) Stem cell\u2013derived, fully differentiated islets for type 1 diabetes. N Engl J Med 393:858\u2013868. https:\/\/doi.org\/10.1056\/nejmoa2506549","journal-title":"N Engl J Med"},{"key":"780_CR47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","volume":"406","author":"K Dahl","year":"2025","unstructured":"Dahl K, Toubro S, Dey S, Duque do Vale R, Flint A, Gasiorek A, Heydorn A, Jastreboff AM, Key C, Petersen SB, Vegge A, Adelborg K (2025) Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study. Lancet 406:149\u2013162. https:\/\/doi.org\/10.1016\/S0140-6736(25)01185-7","journal-title":"Lancet"},{"key":"780_CR48","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/J.JHEP.2024.12.006","volume":"82","author":"L Xiang","year":"2025","unstructured":"Xiang L, Wang G, Zhuang Y, Luo L, Yan J, Zhang H, Li X, Xie C, He Q, Peng Y, Chen H, Li Q, Li X, Guo L, Lv G, Ding Y (2025) Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study. J Hepatol 82:967\u2013978. https:\/\/doi.org\/10.1016\/J.JHEP.2024.12.006","journal-title":"J Hepatol"},{"key":"780_CR49","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/dom.70006","volume":"28","author":"MV Chakravarthy","year":"2025","unstructured":"Chakravarthy MV, Elliott MA, Acosta L, Sonnenberg GE, Bialonczyk D, Wu J, Arg\u00fcelles-Tello FA, Garcia-Reza R, Gonz\u00e1lez-Gonz\u00e1lez JG, Hansen SK, Frias JP (2025) Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: a double-blind, randomized placebo controlled phase 2 trial. Diabetes Obes Metab 28:1673\u20131682. https:\/\/doi.org\/10.1111\/dom.70006","journal-title":"Diabetes Obes Metab"},{"key":"780_CR50","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","volume":"79","author":"M Romero-G\u00f3mez","year":"2023","unstructured":"Romero-G\u00f3mez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS, Bruzone SO, Coronel MJ, Gruz FM, MacKinnon I, George J, Muller K, Lee SS, Caussy C, Petit JM, Ari ZB, Braun M, Katchman H, Lurie Y, Veitsman E, Zuckerman E, Aghemo A, Basili S, Fracanzani AL, Pietrangelo A, Sacerdoti D, Rubio Arce JF, de Guevara Cetina ALL, Chavez-Tapia NC, Reyes EC, Pinzon Te LLB, Baker JR, Ngu J, Orr D, Janczewska E, Matusik P, Stanislaw Sadurski MM, Akinina AV, Alpenidze DN, Bogomolov P, Ermakova PY, Golovach AV, Kim SG, Lee JW, Paik YH, Park JY, Yeon JE, Blasco VV, Madueno FJT, Panero JLC, Perez EM, Cheng PN, Jeng WJ, Liu CJ, Akyuz F, Balaban HY, Basaranoglu M, Demir T, Idilman R, Karakan T, Gyrina O, Kolesnikova OV, Pyvovar SM, Oliinyk O, Skrypnyk I, Bassan I, Bowman WK, Denham DS, Ghalib R, Lawitz EJ, Lucas KJ, Mohseni RH, Sanchez WE, Vierling JM (2023) A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol 79:888\u2013897. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.013","journal-title":"J Hepatol"},{"key":"780_CR51","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/S0140-6736(25)02304-9","volume":"406","author":"F Tacke","year":"2025","unstructured":"Tacke F (2025) The dual GLP-1\u2013glucagon agonist pemvidutide in MASH: a phase 2b trial. Lancet 406:2604\u20132606. https:\/\/doi.org\/10.1016\/S0140-6736(25)02304-9","journal-title":"Lancet"},{"key":"780_CR52","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2337\/dc17-2132","volume":"41","author":"A Digenio","year":"2018","unstructured":"Digenio A, Pham NC, Watts LM, Morgan ES, Jung SW, Baker BF, Geary RS, Bhanot S (2018) Antisense inhibition of protein tyrosine phosphatase 1B with IONIS-PTP-1BRx improves insulin sensitivity and reduces weight in overweight patients with type 2 diabetes. Diabetes Care 41:807\u2013814. https:\/\/doi.org\/10.2337\/dc17-2132","journal-title":"Diabetes Care"},{"key":"780_CR53","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/nejmoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-G\u00f3mez M, Huot-Marchand P, Baudin M, Richard M-P, Abitbol J-L, Broqua P, Junien J-L, Abdelmalek MF (2021) A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med 385:1547\u20131558. https:\/\/doi.org\/10.1056\/nejmoa2036205","journal-title":"N Engl J Med"},{"key":"780_CR54","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","volume":"72","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC (2020) Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study. J Hepatol 72:613\u2013626. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.023","journal-title":"J Hepatol"},{"key":"780_CR55","doi-asserted-by":"publisher","first-page":"1982-LB","DOI":"10.2337\/db25-1982-lb","volume":"74","author":"M Abu-Farha","year":"2025","unstructured":"Abu-Farha M, Abubaker J, Almulla F, Abdul-Ghani M, Norton L, Defronzo Ra, Colca Jr, Mccommis Ks (2025) MPC-directed insulin sensitizer MSDC-0602K combines with tirzepatide to maintain muscle mass\/function and restructure adipose tissue. Diabetes 74:1982-LB. https:\/\/doi.org\/10.2337\/db25-1982-lb","journal-title":"Diabetes"},{"key":"780_CR56","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S2468-1253(23)00198-X","volume":"8","author":"M Noureddin","year":"2023","unstructured":"Noureddin M, Khan S, Portell F, Jorkasky D, Dennis J, Khan O, Johansson L, Johansson E, Sanyal AJ (2023) Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol 8:1094\u20131105. https:\/\/doi.org\/10.1016\/S2468-1253(23)00198-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"780_CR57","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2337\/dc20-2684","volume":"44","author":"KR Klein","year":"2021","unstructured":"Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, Valcarce C (2021) The simplicit1 study: a randomized, double-blind, placebo-controlled phase 1b\/2 adaptive study of ttp399, a hepatoselective glucokinase activator, for adjunctive treatment of type 1 diabetes. Diabetes Care 44:960\u2013968. https:\/\/doi.org\/10.2337\/dc20-2684","journal-title":"Diabetes Care"},{"key":"780_CR58","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.tips.2012.03.014","volume":"33","author":"HS Hansen","year":"2012","unstructured":"Hansen HS, Rosenkilde MM, Holst JJ, Schwartz TW (2012) GPR119 as a fat sensor. Trends Pharmacol Sci 33:374\u2013381. https:\/\/doi.org\/10.1016\/j.tips.2012.03.014","journal-title":"Trends Pharmacol Sci"},{"key":"780_CR59","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/13543784.2024.2321271","volume":"33","author":"DH Hryciw","year":"2024","unstructured":"Hryciw DH, Patten RK, Rodgers RJ, Proietto J, Hutchinson DS, McAinch AJ (2024) GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates. Expert Opin Investig Drugs 33:183\u2013190. https:\/\/doi.org\/10.1080\/13543784.2024.2321271","journal-title":"Expert Opin Investig Drugs"},{"key":"780_CR60","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s11658-021-00276-7","volume":"26","author":"J Zhao","year":"2021","unstructured":"Zhao J, Zhao Y, Hu Y, Peng J (2021) Targeting the GPR119\/incretin axis: a promising new therapy for metabolic-associated fatty liver disease. Cell Mol Biol Lett 26:32. https:\/\/doi.org\/10.1186\/s11658-021-00276-7","journal-title":"Cell Mol Biol Lett"},{"key":"780_CR61","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00018-022-04408-w","volume":"79","author":"E Abati","year":"2022","unstructured":"Abati E, Manini A, Comi GP, Corti S (2022) Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases. Cell Mol Life Sci 79:374. https:\/\/doi.org\/10.1007\/s00018-022-04408-w","journal-title":"Cell Mol Life Sci"},{"key":"780_CR62","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, Praestgaard J, Swan T, Wade T, Perry RG, Goodpaster BH, Roubenoff R (2021) Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open 4:e2033457. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.33457","journal-title":"JAMA Netw Open"},{"key":"780_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04204-0","author":"SB Heymsfield","year":"2026","unstructured":"Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators (2026) Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-026-04204-0","journal-title":"Nat Med"},{"key":"780_CR64","doi-asserted-by":"publisher","first-page":"171210","DOI":"10.1016\/j.peptides.2024.171210","volume":"177","author":"TG P\u00e1lsson","year":"2024","unstructured":"P\u00e1lsson TG, Gilliam-Vigh H, Jensen BAH, Jeppesen PB, Lund AB, Knop FK, Nielsen CK (2024) Targeting the GLP-2 receptor in the management of obesity. Peptides 177:171210. https:\/\/doi.org\/10.1016\/j.peptides.2024.171210","journal-title":"Peptides"},{"key":"780_CR65","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/dom.16047","volume":"27","author":"AZ Haggag","year":"2025","unstructured":"Haggag AZ, Xu J, Butcher L, Pagnussat S, Davies G, Lundqvist S, Wang W, Van Zuydam N, Nelander K, Jha A, Yu H, Boianelli A, Lindmark B, Ollerstam A, Sun X, Wang F, Pan X, Liu H, Chen W, Xu J, Wallenius K, Zhou J (2025) Non-clinical and first-in-human characterization of ECC5004\/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist. Diabetes Obes Metab 27:551\u2013562. https:\/\/doi.org\/10.1111\/dom.16047","journal-title":"Diabetes Obes Metab"},{"key":"780_CR66","doi-asserted-by":"publisher","first-page":"103683","DOI":"10.1016\/j.jpet.2025.103683","volume":"392","author":"W Qi","year":"2025","unstructured":"Qi W, Boca SM, Boianelli A, Fredberg M, Lundqvist S, Davies G, Field J, Brighton CA, Snijder A, Grundevik P, Eckern\u00e4s D, Tr\u00e4ff AM, Polla M, Pettersen D, Omar S, Hansen L, Janz\u00e9n D, Melin J, van Zuydam N, Logue J, Wallenius K (2025) Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist. J Pharmacol Exp Ther 392:103683. https:\/\/doi.org\/10.1016\/j.jpet.2025.103683","journal-title":"J Pharmacol Exp Ther"},{"key":"780_CR67","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1210\/clinem\/dgae550","volume":"110","author":"WB Smith","year":"2025","unstructured":"Smith WB, Nguyen D, Clough T, Schofield J, Kagan MR, Kompa J, He YL, Maratos-Flier E, Jamontt J, Vong L, Schwartzkopf CD, Layne JD, Usera AR, O\u2019donnell CJ, Heldwein KA, Streeper RS, Goldfine AB (2025) A growth differentiation factor 15 receptor agonist in randomized placebo-controlled trials in healthy or obese persons. J Clin Endocrinol Metab 110:771\u2013786. https:\/\/doi.org\/10.1210\/clinem\/dgae550","journal-title":"J Clin Endocrinol Metab"},{"key":"780_CR68","doi-asserted-by":"publisher","first-page":"1252141","DOI":"10.3389\/fendo.2023.1252141","volume":"14","author":"G Xiong","year":"2023","unstructured":"Xiong G, Zhang K, Ma Y, Song Y, Zhang W, Qi T, Qiu H, Shi J, Kan C, Zhang J, Sun X (2023) BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases. Front Endocrinol (Lausanne) 14:1252141. https:\/\/doi.org\/10.3389\/fendo.2023.1252141","journal-title":"Front Endocrinol (Lausanne)"},{"key":"780_CR69","doi-asserted-by":"publisher","first-page":"21224","DOI":"10.1021\/acs.jmedchem.5c01158","volume":"68","author":"P Bhattacharjee","year":"2025","unstructured":"Bhattacharjee P, Dvor\u00e1csk\u00f3 S, Volesky P, Pointeau O, Rutland N, Maccioni L, Godlewski G, Jourdan T, Hassan SA, Cinar R, Iyer MR (2025) Leveraging peripheral CB1 antagonism in 1,4,5,6-tetrahydropyridazine-based amidine substituted sulfonyl analogs for treating metabolic disorders. J Med Chem 68:21224\u201321248. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01158","journal-title":"J Med Chem"},{"key":"780_CR70","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.2337\/db22-0058","volume":"71","author":"E Schreyer","year":"2022","unstructured":"Schreyer E, Obringer C, Messaddeq N, Kieffer B, Zimmet P, Fleming A, Geberhiwot T, Marion V (2022) PATAS, a first-in-class therapeutic peptide biologic, improves whole-body insulin resistance and associated comorbidities in vivo. Diabetes 71:2034\u20132047. https:\/\/doi.org\/10.2337\/db22-0058","journal-title":"Diabetes"},{"key":"780_CR71","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/gels10040260","volume":"10","author":"M Bercea","year":"2024","unstructured":"Bercea M, Lupu A (2024) Recent insights into glucose-responsive concanavalin A-based smart hydrogels for controlled insulin delivery. Gels 10:260. https:\/\/doi.org\/10.3390\/gels10040260","journal-title":"Gels"},{"key":"780_CR72","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1016\/j.molcel.2025.09.020","volume":"85","author":"X Wang","year":"2025","unstructured":"Wang X, Cardoso S, Cai K, Venkatesh P, Hung A, Ng M, Hall C, Coventry B, Lee DS, Chowhan R, Gerben S, Li J, An W, Hon M, Gao M, Liao YC, Accili D, Choi E, chenBai X, Baker D (2025) Tuning insulin receptor signaling using de novo-designed agonists. Mol Cell 85:4064-4081.e9. https:\/\/doi.org\/10.1016\/j.molcel.2025.09.020","journal-title":"Mol Cell"},{"key":"780_CR73","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.omtm.2023.02.003","volume":"28","author":"P Guo","year":"2023","unstructured":"Guo P, Zhang T, Lu A, Shiota C, Huard M, Whitney KE, Huard J (2023) Specific reprogramming of alpha cells to insulin-producing cells by short glucagon promoter-driven Pdx1 and MafA. Mol Ther Methods Clin Dev 28:355\u2013365. https:\/\/doi.org\/10.1016\/j.omtm.2023.02.003","journal-title":"Mol Ther Methods Clin Dev"},{"key":"780_CR74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13619-025-00255-9","volume":"14","author":"P Parsi","year":"2025","unstructured":"Parsi P, Saharkhiz S, Farani MR, Bakhtiyari S, Alipourfard I (2025) Drug-induced regeneration of pancreatic beta cells: an approach to cellular therapeutic targets. Cell Regen 14:39. https:\/\/doi.org\/10.1186\/s13619-025-00255-9","journal-title":"Cell Regen"},{"key":"780_CR75","doi-asserted-by":"publisher","first-page":"1484859","DOI":"10.3389\/fcell.2024.1484859","volume":"12","author":"R Rohban","year":"2024","unstructured":"Rohban R, Martins CP, Esni F (2024) Advanced therapy to cure diabetes: mission impossible is now possible? Front Cell Dev Biol 12:1484859. https:\/\/doi.org\/10.3389\/fcell.2024.1484859","journal-title":"Front Cell Dev Biol"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00780-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:02:34Z","timestamp":1792458154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00780-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":75,"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1007\/s42000-026-00780-5","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ZAE, AIG, and ED have participated in the Synchronize\u2122 CVOT trial of survodutide. ZAE, AIG, and GK have participated in the REIMAGINE 5 study of cagrisema. EM declares no conflict of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}